The reduction of our net loss in 2025 from 2024 was primarily related to the LifeSci Capital LLC judgment expense and reimbursement of legal costs, clinical trial related settlement expenses with A-IR ...
REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ: REVB) is a potentially high-upside clinical-stage biotechnology company focused on immune modulation and inflammatory disease ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results